In summary, we confirmed the significant effect of anti-IL-17A combined with anti-PD-1 therapy in the MSS CRC murine model and observed the effect of antitumor immune response induced by this combination therapy in the tumor microenvironment. This evidence concerns the gene IL17A and neoplasm.